Skip to main
CARL

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed is a promising investment with a strong competitive advantage in the personalized spine implant market. Its innovative, AI-enabled technology has shown promising clinical data and low revision rates, attracting a growing number of surgeries. The company's expanding product offerings, strong patent portfolio, and experienced management team all point towards potential for high revenue growth and profitability in the future. Despite competition in the market, Carlsmed's unique offerings and successful results make it a strong buy for investors.

Bears say

Carlsmed is currently facing a challenging competitive landscape with a crowded market for spine surgery solutions. Additionally, the company's current low-priced products and limited product portfolio may make it difficult to increase profitability in the near future. Furthermore, the company's high valuation, at a 2026 EV/sales multiple of 2.7x, is significantly higher than its small/mid-cap orthopedics and spine group's median multiple of 1.8x, indicating significant downside potential.

Carlsmed Inc (CARL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of Sep 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.